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Abstract: 
Context. Paraquat poisoning is a  medical problem in many parts of Asia 
and the Pacific. The mortality rate is extremely high as there is no effective 
treatment.  
Objective.We analysed data collected during an ongoing cohort study on 
self-poisoning and from a randomized controlled trial assessing the efficacy 
of immunosuppressive therapy in hospitalized paraquat-intoxicated 
patients. The aim of this analysis was to characterise the toxicokinetics and 
toxicodynamics of paraquat in this population.  
Methods.A nonlinear mixed effects approach was used to perform 
toxicokinetic/toxicodynamic population analysis in a cohort of 78 patients.  
Results. The paraquat plasma concentrations were best fitted by a two-
compartment toxicokinetic structural model with first-order absorption and 
first-order elimination. Changes in renal function were used for the 
assessment of paraquat toxicodynamics. The estimates of toxicokinetic 
parameters for the apparent clearance, the apparent volume of distribution 
and elimination half-life were 1.17 L/h, 2.4 L/kg and 87 h, respectively. 
Renal function, namely creatinine clearance, was the most significant 
covariate to explain between patient variability in paraquat clearance.This 
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model suggested that a reduction in paraquat clearance occurred within 24 
to 48 h after poison ingestion, and afterward the clearance was constant 
over time.The model estimated that a paraquat concentration of 429 µg/L 
caused 50% of maximum renal toxicity. The immunosuppressive therapy 
tested during this study was associated with only 8% improvement of renal 
function.  
Conclusion. The developed models may be useful as prognostic tools to 
predict patient outcome  based on patient characteristics on admission and 
to assess drug effectiveness during antidote drug development.  
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Structured summary 
Context. Paraquat poisoning is a  medical problem in many parts of Asia and the Pacific. The 
mortality rate is extremely high as there is no effective treatment. 
Objective.We analysed data collected during an ongoing cohort study on self-poisoning and from 
a randomized controlled trial assessing the efficacy of immunosuppressive therapy in 
hospitalized paraquat-intoxicated patients. The aim of this analysis was to characterise the 
toxicokinetics and toxicodynamics of paraquat in this population. 
Methods.A nonlinear mixed effects approach was used to perform toxicokinetic/toxicodynamic 
population analysis in a cohort of 78 patients. 
Results. The paraquat plasma concentrations were best fitted by a two-compartment toxicokinetic 
structural model with first-order absorption and first-order elimination. Changes in renal function 
were used for the assessment of paraquat toxicodynamics. The estimates of toxicokinetic 
parameters for the apparent clearance, the apparent volume of distribution and elimination half-
life were 1.17 L/h, 2.4 L/kg and 87 h, respectively. Renal function, namely creatinine clearance, 
was the most significant covariate to explain between patient variability in paraquat 
clearance.This model suggested that a reduction in paraquat clearance occurred within 24 to 48 h 
after poison ingestion, and afterward the clearance was constant over time.The model estimated 
that a paraquat concentration of 429 µg/L caused 50% of maximum renal toxicity. The 
immunosuppressive therapy tested during this study was associated with only 8% improvement 
of renal function. 
Conclusion. The developed models may be useful as prognostic tools to predict patient outcome 
based on patient characteristics on admission and to assess drug effectiveness during antidote 
drug development. 
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What was already known about this subject: 
- Although heavily restricted, paraquat remains widely used in the developing world. 
- There is currently limited information on paraquat pharmacokinetics and pharmacodynamics in 
humans 
 - Available prognostic tools for patients outcome after paraquat poisoning were not developed 
based on pharmacology and do not account for differences in treatment effects.  
What this study adds? 
- This is the first  report on population pharmacokinetic and pharmacokinetic/pharmacodynamic 
analyses of paraquat in humans . 
- The developed models can be used to quantitatively characterize treatment effects and therefore 
optimize prognostic tools dedicated to predict patient outcome after poisoning. 
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Introduction 
Paraquat is a commonly used herbicide that causes many deaths from accidental or 
intentional ingestion. Although heavily restricted, it remains widely used in the developing world, 
especially in Asia. Ingestion of more than 15-30 ml of a 20% (w/v) paraquat can result in death 
from multiple organ failure or respiratory failure within a month of intoxication. Due to the lack 
of effective treatment, [1-5]  the mortality rate after paraquat ingestion is around 60%, which is 
much higher than that of other commonly used herbicides such as glyphosate and chlorophenoxy 
herbicides (both around 5-30%). [6, 7] 
Understanding the disposition of paraquat in humans is important for evaluating 
treatments that aim to reduce paraquat concentrations and/or effects. Animal studies indicate that 
paraquat, a cation of a strong base, is rapidly but poorly absorbed from the gastrointestinal tract. 
Only 5-15% reaches the blood stream where the peak level is obtained within 2-6 hours. [3] 
Protein binding of paraquat is very low and paraquat is not metabolized. [8] Small amounts of 
paraquat have been found in bile (post-mortem), indicating that some excretion via bile occurs. 
[8] However, up to 98%of paraquat is excreted unchanged via urine indicating that renal function 
is a key factor in the elimination of paraquat. [9-11] Paraquat toxicokinetics have been studied in 
several animal species including dogs, rats, and rabbits. [11-15] To date, only a few studies have 
focused on paraquat toxicokinetics in humans. [16,17] Moreover, the relationship between 
human toxicokinetics (TK) and toxicodynamics(TD) has not been studied. Over decades, many 
procedures and treatments have been used to modify toxicity of paraquat without any great 
success. [1, 18-20] The best predictors of outcome are volume of ingestion, kidney function and 
age. 
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Acute kidney injury (as measured by a change in creatinine) is very common and very 
strongly predicts death after paraquat poisoning. [21, 22] However, a rise in creatinine is a good 
predictor because it is both an indicator of the extent of ongoing toxicity and of the ability to 
eliminate paraquat. It would be useful to determine the relative contribution of these two factors 
as they have different implications for improving management. 
We report on a nonlinear mixed effects approach to better characterise paraquat kinetics 
and toxicity in a paraquat intoxicated population (population TK/TD or pop TK/TD), the 
uncertainty around TK and TD and the potential covariates that could explain variability in 
paraquat disposition in intoxicated patients.The aims of the present study were: (1) to predict the 
time course of paraquat exposure based on information recorded on admission such as the initial 
kidney function and the ingested volume, (2) to better understand the relationship between 
paraquat exposure and toxicity in humans and (3) to assess the influence of patient characteristics 
on paraquat exposure and toxicity, including  the effects of commonly used treatment 
approaches. 
Materials and methods 
Patients 
The subjects (n = 78) included in the present analysis were from two different sources: 
(1) an ongoing cohort study on self-poisoning and (2) a nested randomized controlled trial (RCT) 
assessing the efficacy ofimmunosuppressive therapy on paraquat poisoning (ISRCTN85372848) 
in Sri Lankan tertiary hospitals. Demographic and clinical data were collected prospectively 
from all consenting patients. The studies were approved by the Ethical Review Committee of the 
Faculty of Medicine, University of Peradeniya, Sri Lanka, and the Human Research Ethics 
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Committee of the Australian National University. Informed written consent was obtained from 
the patients or relatives where this was not possible. 
Paraquat ingestion was initially diagnosed based on patient’s or relative’s history and/or 
by examination of the bottle or label brought to the hospital. Paraquat ingestion was then 
confirmed via these mi-quantitative urine dithionate test (done at least 4 hours after ingestion). 
The amount of paraquat ingested was estimated from the volume described by the patients or 
their relatives. A “little” or “ a teaspoon” was interpreted as equivalent to 5 ml, a “mouthful” to 
25 ml, a “small cup” to 100 ml, a “glass” to 300 ml, and a “bottle” to 400 ml of a commercial 
product containing 20% paraquat. If the patient reported a range of volumes of ingestion, the 
mean volume was used. [23] 
Sixty-eight patients were included in the TD study. The patients were grouped by 
treatment regimen as: standard care (n = 19), standard care  plus placebo (n = 26), and standard 
care plus immunosuppressive therapy (comprising pulse therapy with methylprednisolone and 
cyclophosphamide/MESNA, and dexamethasone) (n = 23) as described elsewhere.20Standard
care consisted of resuscitation (assessment and management of airway, breathing and 
circulation), decontamination using charcoal or Fuller’s earth, and intravenous fluids. 
Haemoperfusion/haemodialysis were not used in any patients. 
Blood and urine sampling 
Serial blood and urine samples were collected for the quantification of paraquat levels at 
admission (t=0), 4, 8, 16, and 24 hour (post admission) and then daily until discharge. After 
discharge, all patients were followed up at one month and three months at the clinic or their 
home. At follow-up, some clinical data, blood and urine samples were collected. Around 6-8 ml 
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blood were withdrawn at each time point and were transferred to two EDTA tubes and mixed 
thoroughly. Then soon after collection,blood samples were centrifuged for 10 minutes at 3000 
rpm and plasma was separated. Urine volumes were not recorded, but where possible 20 ml of 
urine was also collected at these time points, and centrifuged at 2000 rpm for 10 minutes. Clear 
supernatant was then transferred into small tubes. Plasma and urine samples were then carefully 
labeled and immediately transferred to a -20°C freezer, and later shipped to Australia for further 
analysis. 
Paraquat analysis 
Paraquat concentrations in plasma and urine were determined using the LC–MS/MS 
system consisting of an SLC-10AVP system controller, two LC-10AD pumps, an SIL-20AC-HT 
autosampler (Shimadzu, Kyoto, Japan) and an API2000 triple quadrupole(Applied Biosystems 
Inc., Foster City, CA, USA) a mass spectrometer coupled with an electrospray ionization (ESI) 
source and a divert valve.24 Briefly, plasma and urine samples were carried out by one-step
protein precipitation using cold acetonitrile (−20 to −10 ºC). After centrifugation, an aliquot of 
10 µl of supernatant was injected into a KinetexTM hydrophilic interaction chromatography 
(HILIC) column with a KrudKatcherTM Ultra in-line filter. The chromatographic separation was 
achieved using the mobile phase mixture of 250 mM ammonium formate (with 0.8% aqueous 
formic acid) in water and acetonitrile at a flow rate of 0.3 ml/min. The calibration curve was 
linear over the concentration range of 10–5000µg/L, with an LLOQ of 10 µg/L. The inter- and 
intra-day precision (% R.S.D.) was<8.5% with accuracy within the range of 95.1–102.8%. 
Paraquat in plasma and urine samples was stable when stored at -20°C for 3 freeze–thaw cycles. 
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Descriptive statistics and graphic generation 
Graphics and descriptive statistics were generated using GraphPad Prism version 6.01 
(GraphPad Solfware, San Diego, USA).The relationship between paraquat plasma and urine 
concentration over time was also plotted to provide a rough model-independent assessment of 
the expected change over time in renal paraquat clearance. 
Population toxicokinetic-toxicodynamic analysis 
Pop TK: Structural model 
The concentration-time data for paraquat in plasma were analysed by a non-linear mixed-
effect modeling approach using Phoenix NLME version 1.2 Build 6.3.0.395 (Pharsight 
Corporation, Mountain View, CA, USA).  Initial toxicokinetic model selection was performed 
using graphical analysis. Plots of paraquat plasma concentration versus time were generated for 
each individual and examined to determine the appropriate descriptive model. During this 
analysis,  it was assumed that the renal function modified by paraquat had already reached a 
steady state at the time most of plasma paraquat concentrations were measured . This was based 
on the fact that renal function has been shown to decrease exponentially after paraquat ingestion 
before reaching a steady state impaired renal function within the first 48 hours. [13] Based on the 
graphical analysis and the known physicochemical and TK properties of paraquat, a two-
compartment model with first-order absorption and first-order elimination was used as the 
toxicokinetic structural model. Data were fitted using the extended least squared first order 
conditional estimation method (FOCE ELS) as implemented in Phoenix software. The model 
was parameterised in terms of paraquat apparent oral clearance (CLPQ/F), apparent volume of 
distribution of central compartment after oral administration (V1/F), apparent volume of 
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distribution of peripheral compartment after oral administration (V2/F), inter-compartmental 
clearanceafter oral administration (Q/F),  absorption rate constant (Ka) and bioavailability factor 
(F). Ka was fixed to 1 h-1given the lack of data during the absorption phase and given that the
reported mean Tmax in human was 3 h.[3] As the ingested dose was estimated from volume of 
ingestion, the varying doses were imputed as covariates on the bioavailability factor and the 
median dose of paraquat (10 g) was given as the amount administered to each patient. In order to 
avoid numerical issues due to boundaries of F between 0 and 1, the logit of bioavailability factor 
(XF) was first estimated, and the bioavailability factor was subsequently regenerated using the 
following formula: 
F=XF/(1+XF) (1) 
Pop TK: Stochastic model 
Inter-individual variability (IIV) in TK parameters were modeled using an exponential 
model as illustrated below: 
Pi = P*exp(ηi)        (2) 
where Pi is the parameter estimate of the ith individual, P is the typical value for the
population, and ηi is the random effect for individual i, ηwas assumed to be normally distributed 
with a mean value of 0 and a variance of ω2.25IIV terms were added on all the TK parameters.
Residual errors were best described using a combined model (additive and proportional) 
as depicted below: 
Cji = C0ji*(1+ε1ji) + ε2ji        (3) 
where Cji and C0ji are the ith measured (observed) and model predicted paraquat plasma
concentrations for the jth patient, respectively. ε1jiand ε2ji denote the proportional and the additive
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terms for random residual error, respectively. They were assumed to be normally distributed with 
a mean of 0 and variances of and . 
Pop TK: Covariate model 
A stepwise approach was used for toxicokinetic covariate model building with forward 
inclusion followed by backward exclusion. The following covariates were assessed for their 
effects on paraquat disposition: body weight (BW, kg), gender, age (years), amount ingested (g) 
and renal function markers: serum creatinine concentration (sCr, mg/dL) and estimated 
creatinine clearance (eCLcr, L/h). eCLcr was estimated using the Cockcroft-Gault equation. [26] 
Covariates first tested separately according to their biological plausibility and where considered 
to be significant when their addition to the base model led to a decrease of at least 3.84 points in 
the objective function value (OFV) (P-value < 0.05 in the approximate χ2 distribution with 1
degree of freedom). [27, 28] The continuous covariates were normalized to their corresponding 
medians and introduced into the model as shown by Equation 4: 
Pk = θk1*[(Cov/Covmedian) θk2] (4) 
where Pk is the TK parameter, θk1 is the typical value of the TK parameter in the 
population, θk2 is the effect coefficient of the covariate,  Cov is the value of the covariate and 
Covmedian is the median of the covariate in the population under investigation. 
 Categorical covariates were entered into the model using an exponential model. For 
example, the following model was used to assess gender effect on PD parameters: 
Pj = θ0*exp(θ1j *X1j) (5) 
where X1j = 0 and 1 for males and females respectively,θ0 is the typical value of the TD 
parameter in the population and θ1j is the effect coefficient for females. 
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TK model evaluation 
Criteria for selecting the final model included change in the OFV, precision of parameter 
estimation (coefficient of variation (CV) estimates smaller than 50%), [29] graphical analysis 
and quality of goodness-of-fit plots. All of these criteria were taken into account when evaluating 
alternate models.  Lead TK models were evaluated with regards to their accuracy and their 
stability using nonparametric bootstrapping and visual predictive check (VPC) methods. [30] A 
nonparametric bootstrapping method was allowed to assess the stability and uncertainty of the 
final model and estimate the confidence intervals (CI) around parameter estimates in order to 
characterise the precision of their estimation. [31, 32] One thousand replicates of the data sets 
were generated by randomly sampling the patient data, and the final model was fitted 
individually to each of them. All of the model parameters were estimated, and their median and 
95% CI were generated. The VPCs were performed using the final model parameters to simulate 
TK data for 1000 virtual subjects. The 95% prediction interval of simulated concentrations or 
effects was computed and plotted against the observed values. Bayesian estimates of parameters 
for individual patients were also computed from the final model. The final TK model was used to 
generate individual predicted concentrations at times of TD measurements. These individual 
predicted concentration values were used as input for the TD model. TD parameters and their 
associated variability were estimated in a subsequent step as described below. 
Population toxicodynamic model development 
TD: Structural model 
Acute renal failure is a common and important acute toxic effect, and the extent of injury 
predicts death in severe paraquat poisoning. [3, 21] Estimated CLcr  (eCLcr) was used as the 
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marker of paraquat renal toxicity. Initial Pop TD model selection was carried out using graphical 
analysis. Plots of paraquat plasma concentration and TD effect (eCLcr) was constructed for each 
individual and examined to determine the appropriate descriptive model.  Based on this graphical 
analysis, the inhibitory fractional sigmoid Emax model including the baseline was chosen and is 
described as follows: 
E(t) = E0*(1-Emax*Cγ/(ɤ + Cγ)) (6) 
where E(t) is the TD effect (eCLcr) at time t, E0 is the baseline eCLcr of each patient at 
admission, Emax is the maximal fractional decrease of eCLcr caused by paraquat, IC50 is the 
concentration of paraquat causing a 50% of maximum paraquat induced eCLcr decrease, and γ is 
a shape factor characterizing the slope of the response.25
TD: Stochastic model 
Inter-individual variability in TD parameters was also assumed to be log-normally 
distributed and was also modeled using an exponential model.  IIV terms were imputed on all 
TD parameters. 
The residual errors were best described using a log-additive error model as depicted 
below: 
Log Eoij = Log Eji+ εji         (7) 
Where Eoij is the observed effect (eCLcr) for the ith individual at concentration j, Eji is the
individual predicted effect (eCLcr) for the ith individual at concentration j, εjiis the residual error
term. εjiis assumed to be normally distributed with a mean of 0 and a variance equal to σ2.
TD: Covariate model 
The following covariates were tested on the baseline parameter given that they plausibly 
affected baseline CLcr: age, gender, body weight. The effects of different treatments were tested 
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as covariate on Emax, IC50 and γ. Continuous covariates were entered using power models and 
categorical covariates were entered into the model using exponential models as previously 
described. 
When the covariate had more than 2 categories, such as treatment groups, the following 
equations were used: 
Pj = θ0 if treatment group = placebo
Pj = θ0*expθ1j if treatment group = immunosuppressive 
Pj = θ0*expθ2j if treatment group = control (8) 
θ1j and θ2j are the effect coefficients of the covariate 
TD model evaluation 
Lead TD models were also evaluated by a bootstrapping approach and visual predictive 
checks (VPC) as previously described. Bayesian estimates of parametersfor individual patients 
were also computed from the final model. 
Results 
Patient demographics and plasma: urine paraquat ratios 
A total of 698 plasma concentrations from 78 paraquat poisoned patients were included 
in the TK analysis. The demographics of the patients in this study are shown in Table 1. Most 
paraquat plasma concentrations were proportional to urine concentrations with a median ratio 
(plasma:urine) of 0.17 (Fig. 1) in this population. The plasma:urine paraquat ratio was variable 
but overall did not change significantly over time. 
Population toxicokinetic model 
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As described in the methods section, a two-compartment toxicokinetic structural model 
with first-order absorption and first-order elimination was fitted to the data. Parameter estimates 
for the TK base model are presented in Table 2. Given the lack of data in the early distribution 
phase, V2/F value was fixed to 0.17 L/kg based on a sensitivity analysis and taking into account 
previously reported values of paraquat volume of distribution and patient body weights. 
Parameter estimates for the final model are also shown in Table 2. Ingested dose and 
renal function markers were found to be significant covariates on the paraquat bioavailability (F) 
and apparent paraquat clearance (CLPQ), respectively. Estimated CLcr or sCr were tested to assess 
which marker performed better in reflecting renal contribution to CLPQ. Even though smaller 
standard error estimates were obtained when sCr was used (data not shown) as a renal function 
marker, the OFV was significantly higher than when CLcr  was used (Table 2).  Inclusion of body 
weight in the model also significantly reduced the OFV. The goodness-of-fit plots obtained from 
the final toxicokinetic model are shown in Fig. 2, which indicate the model satisfactorily fitted 
the data. 
Population toxicodynamic model 
The final TK model was used to predict individual paraquat concentrations at times of 
TD measurement. Based on graphical analysis, an inhibitory fractional sigmoid Emax model 
including the baseline as shown in Equation (5) was chosen as structural TD model. Parameter 
estimates for the base TD model are presented in Table 3. Parameter estimates for the final 
model are also included in Table 3. 
The final PopTD model (model 7) included age, sex and body weight as covariates on 
baseline eCLcr and method of treatment as covariate on maximum reduction of eCLcr (Emax) 
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(Table 3). Immunosuppression treatment slightly lowered the Emax, by 8% compared to the 
placebo group. The Emax  was 24% lower in the patients treated with standard treatments outside 
the RCT compared to the placebo group (suggesting these two standard treatment only groups 
may differ due to the inclusion criteria for the RCT, in a way not accounted for by measured 
covariates). Goodness-of-fit plots were generated for the final model and the weighted residual 
showed no apparent visual bias for the prediction (Fig. 3). 
Model evaluation 
The accuracy and stability of these models were assessed by nonparametric bootstrap and 
VPC.  As shown in Table 4, the mean population parameters estimated from the bootstrapping 
were stable and comparable to the estimates from the final model. The estimates of the 
parameters from the final model all fell within the 95% CIs of the corresponding parameters 
obtained with the 1,000 bootstraps, indicating that the final model was fairly robust. The VPCs 
showed that approximately 95% of the observed data appear to fall within the 95% confidence 
interval (Fig. 4), suggesting that the final model accurately described the observed data. The 
estimated TK and TK/TD parameters of the individual patients are listed in Table 5. 
Clinical usefulness of the model 
The change of estimated CLPQ over time is shown in Fig.5 showing that after an initial 
rapid decrease the CLPQ was stable over time. The resulting median paraquat concentrations and 
CLcr were simulated for three different values CLcr at admission: the minimum, the median and 
the maximum values (0.3, 6 and 13L/h, respectively) in this cohort of patient. The results 
displayed in Fig. 6 show that the model is able to predict paraquat exposure and toxicity given 
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patient characteristics on admission. It could therefore serve to optimize prognostic tools 
dedicated to predict patients outcome on admission and could serve as a tool to evaluate 
treatment options and candidate antidotes. 
Discussion 
We used a population approach   to describe paraquat disposition and its effects on renal 
function in poisoned patients. A two compartment toxicokinetic model with rapid absorption 
fitted the data well. Renal function was the most important factor influencing paraquat clearance. 
As a function of paraquat concentration, there was a variable but rapid reduction in paraquat 
clearance within 24 to 48 hours, which then was constant and low (around 10ml/min). The time 
at which most of paraquat samples were collected is estimated to be more than 48 hours after 
ingestion.  Whilst paraquat does induce an immediate and variable change in renal function, this 
renal function appears to reach an impaired new steady state renal function within 48 hours. [13] 
Accordingly, the PK model used in this work used the simpler constant impaired renal function 
after paraquat ingestion and did not consider the time variant changes in renal function at early 
times. Renal injury occurred with relatively low concentrations of paraquat (IC50 =429 µg/L). 
This analysis has implications for the development of better prognostic tools, for evaluation of 
candidate antidotes and for the design of the optimal methods to enhance elimination. 
In humans, there is limited data on absorption of paraquat. Any uncertainty on the ingestion 
dose and time of ingestion in our study would be expected to propagate into uncertainty on TK 
and TD parameter estimates. There is only one study that has reported the complete recovery of 
paraquat after oral dosing, [16] and they estimated a V of 1.4 L/kg. If this value is substituted 
into our V/F estimated, the bioavailability(F) is estimated to be around 0.58. 
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Other studies have estimated values for V/F ranging from 1.2 to 2.75 L/kg. [33, 34] and thus 
the V/F of about 2.4 L/kg estimated from our TK model is in the range of estimates. Several 
factors are known to influence paraquat distribution. The extent to which the herbicide is actively 
taken up by lung, liver, kidney and other tissues determines V/F. Therefore, if tissue binding of 
paraquat increased over time, V/F will increase as well. However, a high V/F estimation could be 
due to the over-estimation of the ingested doses. A limitation of this study is the lack of any way 
to accurately quantify ingestion volume, which impacts on estimated TK and TK/TD parameters 
(in both our and all other human studies). Moreover, the uncertainty in the estimation of some 
key covariates (e.g. renal function) also affects the degree of precision in these models. 
The deep compartment consists of tissues where the toxic effects are manifested (in 
particular lungs and kidneys) and other tissues which act as a reservoir. Paraquat is actively taken 
up into type II pneumocytes resulting in slow elimination of paraquat from lung compared to 
other tissues. [1] Active renal uptake and excretion of paraquat is also concentration dependent 
and saturable; [35] consequently, high levels of paraquat are seen in kidney. Impairment of 
kidney function in turn leads to higher concentrations of paraquat in the plasma. [12] Muscle is 
an important paraquat reservoir explaining the persistence of paraquat in plasma and urine for 
several weeks after exposure. [16] The long elimination half-life (t1/2 β) of 3-4 days in our study 
reflects the combined effects of reduced clearance from the decline in renal function and the 
slow release of paraquat from tissues into the circulation. 
An obvious large change in paraquat renal clearance in these patients was not observed and 
the plasma/urine paraquat ratio changed little over time (Fig. 1) which could wrongly suggest a 
simple and static first-order elimination process. Modeling individual patient concentrations did 
demonstrate a progressive decline in clearance. Several previous reports also indicate that 
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paraquat renal clearance (and total clearance) is a nonlinear function of time. A large decrease 
over time in CLPQ occurs with nephrotoxicity.[8, 13] At low doses, CLPQ may exceed 12 L/h in 
humans with normal kidney function.36The mean estimate for CLPQ/F (1.17 L/h) obtained from
our PopTK model is considerably lower than that reported in some previous human case reports 
(mean = 4.39 L/h), [34] and they showed a rapid change in CLPQ/F from 8.77 to 2.72 L/h within 
12 h. Substituting F = 0.58 into CLPQ/F yields an estimated mean CLPQ of 0.68L/h (11.33 
ml/min) in our study.  This CLPQ is similar to those reported by Houze et al which range from 
0.47 to 0.59 L/h (7.9 to 9.9 ml/min). [16] It seems likely we and Houze et al have missed a very 
short early phase of high CLPQ reported by others. [34, 36] The low CLPQ reflects the very rapid 
onset of paraquat induced renal impairment. [12, 13, 35, 37-39] Therefore, the low estimated 
CLPQ/F in the present study reflects that most blood samples were collected 6 or more hours 
post-paraquat ingestion when renal damage was already established. While a further modest 
decline in estimated CLPQ/Fwasfound over 24 to 48 h (Fig. 5), thereafter the estimated clearances 
were constant over time. 
In our analysis, the effect of the eCLcr, (reflecting GFR), on CLPQ was lower than one would 
expect. This probably reflects errors in the estimate of GFR rather than the model. [40] The 
Cockcroft-Gault equation has at least a 30% variance around actual renal function in chronic 
kidney disease population with sCr≤ 1.5 mg/dl. [41] It also performs very poorly when Cr is 
changing (i.e. it assumes steady-state). However, other estimation methods perform equally 
poorly (when compared with gold standard methods such as iohexol clearance). Future studies 
should ideally use more accurate direct measurements of GFR or creatinine clearance. 
The model suggested a very small effect of immunosuppressive treatment (8% lower Emax 
compared to placebo group).This is consistent with the clinical outcomes reported in this trial 
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[20] which was a very small favourable treatment effect that was not statistically significant. 
However, this difference was less than that seen in the non-RCT patients (24% lower 
Emax);which might be a result of the RCT inclusion criteria aiming to select people who had 
significant poisoning but also who would survive long enough to measure renal injury. Further, 
anotherRCT has also reported that immunosuppressive therapy did not improve renal function.2, 
[42] So, these results should not be used to imply that immunosuppressive treatment has 
substantial effects on renal injury. 
Model predictions may serve a number of purposes. From a clinical perspective, they can 
identify patients on admission who are very likely to develop kidney dysfunction. Using the TK 
model developed in this study, a paraquat plasma concentration-time profile can be predicted for 
individual patients on admission. Thereafter, a combination of the TK and the TD model could 
predict kidney function, namely creatinine clearance, changes over time. Prediction of 
toxicokinetics and acute kidney injury might in turn be used to identify patients most likely to 
benefit from enhanced elimination or who are most suitable for inclusion into clinical trials of 
strategies to prevent kidney injury and other manifestations of paraquat toxicity. 
Conclusion 
Renal function was the most significant covariate to explain between patient variability in 
paraquat clearance. Renal injury occurred with relatively low concentrations of paraquat (IC50 
=429 µg/L). A reduction in paraquat clearance occurred over 24 to 48 h after paraquat ingestion, 
and afterward the clearance was constant and low. The low clearance (around 10ml/min) and 
long half-life (3-4 days) in these cases suggest further studies of extracorporeal elimination 
would be worth exploring, as it is clear much greater clearance can be obtained by such methods. 
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[39] After optimal methods for enhancing elimination have been developed, large clinical trials 
will still be needed to determine if such methods can improve clinical outcomes. 
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Legends to figures 
Figure 1. Scatter plot of plasma versus urine paraquat concentrations. 
Figure 2. Diagnostic goodness-of-fit plots from the final population toxicokinetic model: 
Conditional weighted residuals versus time after ingestion (A), Conditional weighted versus 
population predicted concentration (B), Observed versus individual predicted concentrations (C), 
Observed versus population predicted concentrations (D). The open circles are the observed data, 
and the plotted line is the line of identity (y=x) 
Figure 3. Diagnostic goodness-of-fit plots from the final population toxicodynamics model: 
Conditional weighted residuals versus paraquat plasma concentrations (A), Conditional weighted 
residuals versus population predicted CLcr (B), Observed versus individual predicted CLcr (C), 
Observed versus population predicted CLcr (D). The open circles are the observed data, and the 
plotted line is the line of identity (y=x) 
Figure 4. Scatter plots for visual predictive check: observed and simulated concentrations versus 
time (A),observed and simulated CLcr versus paraquat plasma concentrations (B). Percentiles (5, 
50 and 95) were calculated using the final PopTK and TD model. 
Figure 5.Time course of empirical Bayes estimates of CLPQ   in PQ-poisoning patients. 
Figure 6. Time course of median predicted PQ concentrations for initial CLcr of  0.3, 6 
and13L/h. 
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Tables 
Table 1. Demographics of the patients enrolled in the population toxicokinetic and 
toxicodynamic studies 
Characteristics Toxicokinetic study (n= 78) 
Median (Range) 
Toxicodynamic study (n= 
68)Median (Range) 
Male/female (n) 52/26 45/23 
Age (y) 28 (14-76) 30 (14-76) 
Weight (kg) 51 (35-66) 51 (35-66) 
sCr (mg/dl) 2 (0.3-12.6) 2 (0.3-12.6) 
CLcr (L/h) 1.89 (0.29-13.25) 2.05 (0.29-13.25) 
Ingestion volume (ml) 50 (5-750) - 
Ingestion dose (g) 10 (1-150) - 
sCr, serum creatinine; CLcr, creatinine clearance 
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Table 2. Toxicokinetic model of paraquat 
OFV, objective function value; IIV, Inter-individual variability; F, bioavailability;V1/F, apparent volume of central compartment; CL/F, clearance; Q/F, apparent 
inter-compartmental clearance; XF, the logit of bioavailability; BW, body weight; %CV, coefficient of variation; %SE, standard error 
Description of model OFV Parameter (RSE(%)) Covariate effect (RSE(%)) IIV % (RSE(%)) 
V1/F CL/F Q/F V1/F CL/F XF V1/F CL/F XF 
Base model with mixed 
error model 
9496 16.46 
(16) 
0.58 
(15) 
1.74 
(8) 
- - - 91 
(20) 
125 
(44) 
142 
(38) 
 Final model with 
ingestion dose  effect on 
F, CLcr effect on CLPQ, 
BW on V1 
9449 13.63 
(16) 
0.15 
(31) 
0.84 
(11) 
BW: 1.0 CLcr: 1.57 
(10) 
Dose: 6.93E-8 
(42) 
89 
(18) 
124 
(57) 
142 
(37) 
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Table 3. Toxicodynamic model of paraquat 
OFV, objective function value;; IIV, Inter-individual variability; IC50, the concentration of PQ causing a 50% of maximum PQ induced-creatinine clearance 
reduction; γ, a shape factor characterising the slope of the response; E0, the baseline creatinine clearance; Emax, the maximum fractional decrease of creatinine 
clearance; BW, body weight; %CV, coefficient of variation; %SE, standard error 
Description of model OFV Parameter (RSE(%)) Covariate effect (RSE(%)) IIV % (RSE(%)) 
IC50 γ E0 Emax E0 Emax IC50 γ E0 Emax 
Base model with log-
additive error model 
745 346 
(3) 
24.02 
(2) 
3.35 
(2) 
0.55 
(2) 
- - 373 
(62) 
4 
(0.01) 
38 
(1) 
6 
(0.02) 
Final model with age, 
sex and BW effect on 
E0,Treatment effect on 
Emax 
727 207 
(1) 
5.02 
(0.7) 
3.23 
(0.7) 
0.62 
(0.7) 
Age: -0.07 (0.7) 
Male: 0.14 (0.7) 
BW: 1.39 (0.7) 
Active: -0.08 
(0.7) 
Control: -0.27 
(0.7) 
369 
(20.2) 
31 
(0.1) 
27 
(0.1) 
6 
(0.01) 
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Table 4. Results of nonparametric bootstrap analysis of paraquat population toxicokinetics and toxicodynamics 
Parameter Final model Bootstrap 
Mean %CV 2.5%CI 97.5% CI Mean %CV Median 2.5% CI 97.5% CI 
Toxicokinetics 
θV (L) 13.63 16 9.28 17.98 14.64 36 13.59 6.62 27.32 
θCL (L/h) 0.15 31 0.06 0.24 0.22 86 0.16 0.02 0.73 
θQ (L/h) 0.84 11 0.67 1.02 0.87 27 0.85 0.48 1.35 
Proportional 
residual error (%) 
0.48 39 0.12 0.84 0.80 148 0.44 0.11 4.38 
Additive residual 
error (µg/L) 
0.89 ² - - 1.26 77 0.98 0.1 3.7 
Toxicodynamics 
θIC50 (µg/L) 207 1.04 202.91 211.36 286 80 208 126 806 
θγ 5.02 0.74 4.94 5.09 5.49 15 5.15 3.97 6.84 
θE0 (L/h) 3.23 0.73 3.18 3.27 3.17 9 3.17 2.69 3.77 
θEmax (L/h) 0.62 0.72 0.61 0.63 0.62 7 0.62 0.54 0.71 
Log additive 
residual error(L/h) 
0.58 - - - 0.58 6 0.58 0.51 0.64 
θV, typical value of the volume distribution; θCL, typical value of the clearance, θQ, typical value of the inter-compartmental clearance; θXF, typical value of the 
logit of bioavailability; θIC50, typical value of the concentration of PQ causing a 50% of maximum PQ induced-creatinine clearance reduction; θγ, typical value of 
a shape factor characterising the slope of the response; θE0, typical value of the baseline creatinine clearance; θEmax, typical value of the maximum fractional 
decrease of creatinine clearance; %CV, coefficient of variation; CI, confidence interval 
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Table 5. Distribuion of empirical Bayes estimates of population toxicokinetic and toxicodynamic 
parameters 
Model Parameter Mean SD 2.5% 97.5%CI 
Toxicokinetics (n = 78) V1 (L/kg) 0.34 0.21 0.28 0.38 
V2 (L/kg) 2.06 1.73 1.67 2.44 
Ka(h-1) 0.93 0.40 0.84 1.0 
CLPQ (L/h) 1.17 3.52 0.32 2.01 
t1/2 β(h) 86.98 189.2 41.53 132.4 
Toxicodynamics (n = 68) IC50(µg/L) 429 893 213 645 
Emax(L/h) 0.62 0.006 0.61 0.62 
V1, volume of distribution of central compartment; V2, volume of distribution of peripheral compartment; Ka, 
absorption rate constant; CLPQ, paraquat clearance; t1/2 β, elimination half-life; IC50, the concentration of PQ causing 
a 50% of maximum PQ induced-creatinine clearance reduction; Emax, the maximum fractional decrease of creatinine 
clearance; SD, standard deviation; %CI, confidence interval 
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Figure 1. Scatter plot of plasma versus urine paraquat concentrations. 
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Figure 2. Diagnostic goodness-of-fit plots from the final population toxicokinetic model: Conditional weighted 
residuals versus time after ingestion (A), Conditional weighted versus population predicted concentration 
(B), Observed versus individual predicted concentrations (C), Observed versus population predicted 
concentrations (D). The open circles are the observed data, and the plotted line is the line of identity (y=x)  
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Figure 3. Diagnostic goodness-of-fit plots from the final population toxicodynamics model: Conditional 
weighted residuals versus paraquat plasma concentrations (A), Conditional weighted residuals versus 
population predicted CLcr (B), Observed versus individual predicted CLcr (C), Observed versus population 
predicted CLcr (D). The open circles are the observed data, and the plotted line is the line of identity (y=x) 
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Figure 4. Scatter plots for visual predictive check: observed and simulated concentrations versus time 
(A),observed and simulated CLcr versus paraquat plasma concentrations (B). Percentiles (5, 50 and 95) 
were calculated using the final PopTK and TD model.  
121x165mm (600 x 600 DPI)  
Page 39 of 40
British Pharmacological Society
British Journal of Clinical Pharmacology
Figure 5.Time course of empirical Bayes estimates of CLPQ   in PQ-poisoning patients. 
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Figure 6. Time course of median predicted   PQ concentrations for initial CLcr of  0.3, 6 and13L/h. 
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